These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38286177)

  • 1. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial.
    Johansen ND; Modin D; Skaarup KG; Nealon J; Samson S; Dufournet M; Loiacono MM; Harris RC; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    Clin Microbiol Infect; 2024 Nov; 30(11):1453-1459. PubMed ID: 38286177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
    Lassen MCH; Johansen ND; Modin D; Nealon J; Samson S; Dufournet M; Loiacono MM; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Krause TG; Biering-Sørensen T
    Diabetes Obes Metab; 2024 May; 26(5):1821-1829. PubMed ID: 38586966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults with Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial.
    Christensen J; Johansen ND; Modin D; Janstrup KH; Nealon J; Samson SI; Loiacono MM; Harris R; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Gislason GH; Køber L; Landray MJ; Sivapalan P; Jensen JUS; Biering-Sørensen T
    Circ Cardiovasc Qual Outcomes; 2024 Aug; ():. PubMed ID: 39215646
    [No Abstract]   [Full Text] [Related]  

  • 4. High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults.
    Palmu AA; Pepin S; Syrjänen RK; Mari K; Mallett Moore T; Jokinen J; Nieminen H; Kilpi T; Samson SI; De Bruijn I
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13270. PubMed ID: 38569647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: A post hoc analysis of the DANFLU-1 randomized clinical trial.
    Christensen J; Johansen ND; Janstrup KH; Modin D; Skaarup KG; Nealon J; Samson S; Loiacono M; Harris R; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Gislason GH; Køber L; Landray MJ; Sivapalan P; Jensen JUS; Biering-Sørensen T
    J Infect; 2024 Nov; 89(5):106276. PubMed ID: 39303788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pragmatic Randomized Feasibility Trial of Influenza Vaccines.
    Johansen ND; Modin D; Nealon J; Samson S; Salamand C; Loiacono MM; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    NEJM Evid; 2023 Feb; 2(2):EVIDoa2200206. PubMed ID: 38320035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021-2022 influenza season.
    Bricout H; Levant MC; Assi N; Crépey P; Descamps A; Mari K; Gaillat J; Gavazzi G; Grenier B; Launay O; Mosnier A; Raguideau F; Watier L; Harris RC; Chit A
    Clin Microbiol Infect; 2024 Aug; ():. PubMed ID: 39187126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial.
    Hollingsworth R; Palmu A; Pepin S; Dupuy M; Shrestha A; Jokinen J; Syrjänen R; Nealon J; Samson S; De Bruijn I
    Am Heart J; 2021 Jul; 237():54-61. PubMed ID: 33722585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and public health impact of using high dose quadrivalent influenza vaccine in the French older adults population.
    Alvarez FP; Allard L; Bianic F; Bricout H; Crépey P; Gaillat J; Gavazzi G; Mosnier A; Launay O; Levant MC; Proshenska D; de Courville C
    J Med Econ; 2024; 27(1):1300-1307. PubMed ID: 39286871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
    Rumi F; Basile M; Cicchetti A; Alvarez FP; Azzi MV; Muzii B
    Front Public Health; 2023; 11():1200116. PubMed ID: 38026422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
    Vardeny O; Kim K; Udell JA; Joseph J; Desai AS; Farkouh ME; Hegde SM; Hernandez AF; McGeer A; Talbot HK; Anand I; Bhatt DL; Cannon CP; DeMets D; Gaziano JM; Goodman SG; Nichol K; Tattersall MC; Temte JL; Wittes J; Yancy C; Claggett B; Chen Y; Mao L; Havighurst TC; Cooper LS; Solomon SD;
    JAMA; 2021 Jan; 325(1):39-49. PubMed ID: 33275134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
    Skaarup KG; Lassen MCH; Modin D; Johansen ND; Loiacono MM; Harris RC; Lee JKH; Dufournet M; Vardeny O; Peikert A; Claggett B; Solomon SD; Jensen JUS; Biering-Sørensen T
    J Infect; 2024 Jul; 89(1):106187. PubMed ID: 38795774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    van der Pol S; Zeevat F; Postma MJ; Boersma C
    Vaccine; 2024 May; 42(15):3429-3436. PubMed ID: 38631948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older Adults.
    Zeevat F; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2023 Apr; 26(4):461-464. PubMed ID: 36509369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
    Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
    Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial.
    Johansen ND; Modin D; Nealon J; Samson S; Salamand C; Larsen CS; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    Pilot Feasibility Stud; 2022 Apr; 8(1):87. PubMed ID: 35449028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial.
    Colmegna I; Useche ML; Rodriguez K; McCormack D; Alfonso G; Patel A; Ramanakumar AV; Rahme E; Bernatsky S; Hudson M; Ward BJ
    Lancet Rheumatol; 2020 Jan; 2(1):e14-e23. PubMed ID: 38258270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.